RxDoctor Payments Data

Sara Zaleta, MD

Internal Medicine · Kaufman, TXNPI 1336106913

Payments from drug & device makers

$10,848in general payments, 2019–2025

Across 648 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$869
  • Pfizer$777
  • Antares Pharma, Inc.$541
  • Boehringer Ingelheim$482
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$10,848100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)111$1,673
Novo Nordisk86$1,217
AstraZeneca51$869
Pfizer44$777
Antares Pharma, Inc.20$541
Boehringer Ingelheim28$482
Lilly USA, LLC29$461
Amgen26$455
Amarin Pharma, Inc.24$427
Otsuka America Pharmaceutical, Inc.17$371
Astellas Pharma US Inc16$313
Sanofi-aventis U.S. LLC14$298
GSK19$275
Corcept Therapeutics5$194
Merck12$185
Sunovion Pharmaceuticals Inc.14$170
Abbott9$169
Dexcom, Inc.12$168
Mylan Specialty L.p.11$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$152
Bayer7$130
Johnson & Johnson9$128
Exact Sciences7$111
Sumitomo Pharma America, Inc.4$84
Novartis5$70
Lundbeck LLC4$69
Halozyme Inc4$66
Biohaven Pharmaceuticals, Inc.5$65
Takeda Pharmaceuticals U.S.A., Inc.4$56
Genentech USA, Inc.3$50
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$46
Idorsia Pharmaceuticals US Inc3$46
Currax Pharmaceuticals LLC3$44
Aimmune Therapeutics, Inc.2$42
Biohaven Pharmaceutical Holding Company Ltd.2$41
Teva Pharmaceuticals USA, Inc.3$38
Axsome Therapeutics, Inc.1$32
Phathom Pharmaceuticals, Inc.2$29
Ironshore Pharmaceuticals Inc.2$26
Viatris Specialty LLC1$24
Sanofi Pasteur Inc.2$23
Paratek Pharmaceuticals, Inc.1$22
Kyowa Kirin, Inc.1$22
Tris Pharma Inc1$21
Vertex1$20
Springworks Therapeutics, Inc.1$20
Acerus Pharmaceuticals Corporation1$18
Bioventus LLC1$17
Almatica Pharma LLC1$16
Cranial Technologies, Inc1$16
Dynavax Technologies Corporation1$16
Philips North America LLC1$14
Medtronic1$14
Xeris Pharmaceuticals, Inc.1$14
Assertio Therapeutics, Inc.1$14
Arbor Pharmaceuticals, Inc.1$13
Athena Bioscience, LLC1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,848 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$79,871
Medicare patients
217
Services billed
1,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$87,703
OzempicSemaglutide65$87,531
EliquisApixaban82$76,072
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$70,064
XareltoRivaroxaban36$39,323
JanuviaSitagliptin Phosphate21$31,728
ProliaDenosumab17$28,732
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$27,328
FarxigaDapagliflozin Propanediol25$23,062
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$16,690
EntrestoSacubitril/Valsartan11$14,413
LinzessLinaclotide20$13,802
TrulicityDulaglutide13$13,170
Soliqua 100-33Insulin Glargine/Lixisenatide15$13,090
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$11,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$275$97,118129 claims
Boehringer IngelheimJardiance$482$87,70399 claims
Novo NordiskOzempic$1,217$87,53165 claims
PfizerEliquis, Lyrica$777$81,65494 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$869$56,31181 claims
Johnson & JohnsonXarelto$128$39,32336 claims
MerckJanuvia$185$31,72821 claims
AmgenProlia$455$28,73217 claims
NovartisEntresto$70$14,41311 claims
AbbVieLinzess$1,673$13,80220 claims
Lilly USA, LLCTrulicity$461$13,17013 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$298$13,09015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Kaufman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →